Assertio Holdings, Inc.
HealthcareNASDAQ:ASRT · NASDAQ Capital Market
+$0.01 today
Vol 0.49M · Avg 0.33M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-32.3%
avg -70.2%
ROIC
-12.4%
avg -20.6%
ROA
-11.4%
avg -16.2%
Analysis
ROA is currently the strongest return metric at -11.4% versus its period average of -16.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mark L. Reisenauer | Chief Executive Officer & Director | $1.13M | — | 60 | $26,667.00 | 0.41% |
Paul Schwichtenberg | President & Chief Operating Officer | $707,248.00 | — | 55 | $27,888.00 | 0.43% |
Ajay Patel | Executive Vice President & Chief Financial Officer | $682,815.00 | — | 42 | $21,128.00 | 0.33% |
Howard J. Franklin | Senior Vice President of Medical | — | — | — | — | — |
Sam Schlessinger | Executive Vice President & General Counsel | — | — | 44 | $21,128.00 | 0.33% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$6,806.15
Net Sentiment
$6,806.15
Net selling
Most Active
Stark David Matthew
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $6,806.15 over the last 12 months. That adds up to net selling of $6,806.15. Stark David Matthew was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +55.7% | -6.6% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +55.7% over three years. Forward estimates point to Revenue at -6.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Fortress Biotech, Inc.
NASDAQ:FBIO
$92.02M
XBiotech Inc.
NASDAQ:XBIT
$71.34M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Pulmonx Corporation
NASDAQ:LUNG
$57.86M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
InterCure Ltd.
INCR
$47.79M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
Nutriband Inc.
NTRB
$41.21M
Lite Strategy, Inc.
LITS
$25.22M
Who manages ASRT?
Assertio Holdings, Inc. (ASRT) lists 5 active executives. The top listed executive is Howard J. Franklin, Senior Vice President of Medical.
Are ASRT insiders buying or selling?
Recent insider activity shows net selling of $1.52M.
Explore More
Continue the stock analysis
Jump to another research area for this company.